

Fiducian Growth Managed Shares Portfolio

Monthly Report - February 2025



Portfolio performance

	1 m	3 mths	6 mths	1 yr	2yrs	3yrs	4yrs	5yrs	7yrs	9yrs	10yrs
Total Portfolio Return	-7.8%	-1.7%	13.1%	24.4%	19.8%	15.8%	12.4%	14.8%	14.1%	16.1%	13.8%
Income	0.2%	0.1%	0.3%	0.9%	1.3%	1.6%	1.7%	1.6%	1.9%	2.3%	2.4%
S&P/ASX 100 Accumulation Index	-3.9%	-2.7%	2.4%	9.9%	10.4%	9.8%	10.1%	9.2%	9.0%	10.4%	7.7%

Note: Portfolio performance as set out in the table above is a notional value only. The total return calculation assumes re-investment of all dividends and rebalancing of the portfolio to equal stock weightings after each stock change. In practice, each investor's portfolio is distinct with its own price and return history, while dividends are fully distributed and not re-invested and rebalancing occurs only intermittently. Returns over a year are annualised and since 1 July 2017 have been net of an investment management fee of 0.4% per annum.

Portfolio commentary

The portfolio fell 7.8% in February, underperforming the benchmark (ASX 100 Accumulation Index) decline of 3.9%. Stocks within the portfolio are well-diversified, growth-oriented blue-chips and as such, the portfolio could be expected to do particularly well in periods of stronger economic growth but could underperform the index in periods of slower growth, which tend to favour more defensive portfolios.

The broad Australian share market (ASX 200 Accumulation Index) declined by 3.8% in February. Over the month, the best performing sectors were Utilities (+3.2%) and Telecoms (+2.6%). Information Technology (-12.3%), Healthcare (-7.7%), Listed Property (-6.4%) and Energy (-5.2%) were the notable detractors during the month.

The two contributors to relative portfolio performance over the month were Worley (+5.3%) and Telix (-3.0%). Worley gained on strong half-year results. Telix Pharmaceuticals provided a positive revenue forecast alongside the release of its half-year results.

The largest detractors from portfolio performance during the month were Wisetech Global (-27.7%), Cochlear (-19.0%) and NextDC (-10.2%). Wisetech Global suffered on further negative news related to its management team. Cochlear fell on disappointing half-year results. NextDC fell as technology stocks continued to experience selling pressure globally.

Beach Energy was replaced by Pinnacle Investment Management during the month. Pinnacle offers third party distribution, fund infrastructure and support to various investment managers. The company is projected to continue to enjoy solid revenue growth through opportunities in the managed-accounts market.


As at the end of February, the portfolio is forecast to provide investors with a prospective yield of 1.0% for the 2024-25 financial year, before the consideration of franking credits. With an average franking level of around 40.1%, the portfolio currently provides investors with an estimated grossed-up yield of around 1.2% per annum.

Portfolio holdings

Shares	P/E	Yield
Aristocrat Leisure	29.2	1.2%
Cochlear	38.8	1.8%
CSL	25.9	1.8%
Neuren Pharmaceuticals	17.2	0.0%
NextDC		0.0%
Pinnacle Investment	34.0	2.6%
Pro Medicus	251.0	0.2%
REA Group	56.7	1.0%
Santos	10.0	5.1%
Technology One	70.2	0.8%
Telix Pharmaceuticals	86.2	0.0%
WiseTech Global	79.8	0.3%
Worley	17.4	3.7%
Xero	106.1	0.0%
Average	67.7	1.0%

FY25 estimated price to earnings ratios and yields at end of Feb 2025.
Source: www.marketscreener.com

Portfolio performance



Fiducian Investment Management Services Limited

Issued by Fiducian Investment Management Services Limited ABN 28 602 441 814 AFS Licence number 468211. This document provides general information only. It does not have regard to your objectives, financial situation or needs. We recommend that you seek financial planning advice, and consider whether this investment is appropriate to your objectives, financial situation and needs before making any investment decision.
The information has been compiled from sources considered reliable, but is not guaranteed. Past performance is not indicative of future performance and we do not guarantee the performance of the Fund or any specific rate of return. Potential investors should also obtain and consider the relevant Target Market Determination (TMD) and Product Disclosure Statement (PDS) (available from your financial adviser and via fiducian.com.au) before making a decision about whether to acquire or continue to hold any financial product.